Ruxolitinib May Be Effective in Refractory Chronic GVHD - Hematology Advisor
Ruxolitinib shows efficacy in refractory sclerotic chronic graft vs host disease (cGVHD), with 49% partial response at 6 months and 77% ongoing response at 12 months, though 20.8% treatment failure rate and 2.2% nonrelapse mortality observed.
Related Clinical Trials
Reference News
Ruxolitinib showed high rates of skin/joint responses, overall cGVHD responses, low NRM, high FFS, and improved PROs in refractory sclerotic cGVHD patients. 49% achieved PR in skin/joints at 6 months, with 47% overall cGVHD PR. Treatment failure was 20.8%, NRM 2.2%, and FFS 77.1% at 12 months. Ruxolitinib was well-tolerated with no new safety signals.
Ruxolitinib shows efficacy in refractory sclerotic chronic graft vs host disease (cGVHD), with 49% partial response at 6 months and 77% ongoing response at 12 months, though 20.8% treatment failure rate and 2.2% nonrelapse mortality observed.